Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
07 Aug 2024
// BUSINESSWIRE
15 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sumitomo-pharma-announces-that-dsp-5336-has-received-fda-fast-track-designation-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia-302196812.html
27 Jun 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/following-sweeping-us-layoffs-amid-revenue-decline-sumitomo-pharmas-new-head-weighs-japan
14 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sumitomo-pharma-presents-new-clinical-data-on-dsp-5336-at-the-european-hematology-association-2024-congress-302173004.html
22 May 2024
// ENDPTS
https://endpts.com/sumitomo-and-japan-national-institutes-universal-influenza-vaccine-enters-clinical-trials/
13 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sumitomo-pharma-announces-fda-acceptance-of-supplemental-new-drug-application-for-vibegron-in-men-with-overactive-bladder-symptoms-receiving-pharmacological-therapy-for-benign-prostatic-hyperplasia-302143418.html
Inspections and registrations
ABOUT THIS PAGE
Sumitomo Pharma is a supplier offers 13 products (APIs, Excipients or Intermediates).
Find a price of Lurasidone Hydrochloride bulk with DMF offered by Sumitomo Pharma
Find a price of Zonisamide bulk with DMF offered by Sumitomo Pharma
Find a price of Amrubicin bulk offered by Sumitomo Pharma
Find a price of Droxidopa bulk offered by Sumitomo Pharma
Find a price of Enoxacin bulk offered by Sumitomo Pharma
Find a price of Meropenem bulk offered by Sumitomo Pharma
Find a price of Ranirestat bulk offered by Sumitomo Pharma
Find a price of Rimacalib bulk offered by Sumitomo Pharma
Find a price of Sm-216601 bulk offered by Sumitomo Pharma
Find a price of Smp 797 bulk offered by Sumitomo Pharma
Find a price of Sparfloxacin bulk offered by Sumitomo Pharma
Find a price of SMP-986 bulk offered by Sumitomo Pharma
Find a price of SMP-028 bulk offered by Sumitomo Pharma
LOOKING FOR A SUPPLIER?